Oncocyte to Participate in "J.P. Morgan Week" and Host Investor Meetings
Oncocyte to Participate in "J.P. Morgan Week" and Host Investor Meetings
January 13-16, 2025, San Francisco, CA
2025年1月13日至16日，加利福尼亞州舊金山
IRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend "J.P. Morgan Week," coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, from January 13-16, 2025. During this period, Oncocyte will host one-on-one meetings with interested investors.
加利福尼亞州歐文，2024年12月9日（環球新聞通訊社）——oncocyte corp.（納斯達克：OCX），一家領先的診斷科技公司，今天宣佈首席執行官喬希·裏格斯和首席財務官安德麗亞·詹姆斯將出席與第43屆年度JP摩根醫療會議同時進行的「JP摩根周」，該會議將在2025年1月13日至16日於舊金山舉行。在此期間，oncocyte將與感興趣的投資者進行一對一的會議。
Investors wishing to schedule a meeting are encouraged to contact Julie Silber at PCG Advisory via email at jsilber@pcgadvisory.com.
希望安排會議的投資者可以通過電子郵件聯繫PCG顧問的朱莉·西爾伯，郵箱是jsilber@pcgadvisory.com。
Event: "J.P. Morgan Week"
Dates: January 13-16, 2025
Location: San Francisco, CA, USA
活動：「JP摩根周」
日期：2025年1月13日至16日
地點：加利福尼亞州舊金山，美國
About Oncocyte
Oncocyte is a diagnostics technology company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft is a clinical blood-based solid organ transplantation monitoring test. GraftAssure is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit . For more information about our products, please visit the following web pages:
關於Oncocyte
Oncocyte是一家診斷技術公司。該公司的檢測旨在幫助醫生及其患者獲得更清晰和更有信心的信息。VitaGraft是一種臨床血液基固體器官移植監測測試。GraftAssure是一種僅限研究用途（RUO）的血液基固體器官移植監測測試。DetermaIO是一種基因表達測試，用於評估腫瘤微環境，預測對免疫療法的反應。DetermaCNI是一種用於監測癌症患者治療效果的血液基監測工具。有關Oncocyte的更多信息，請訪問。有關我們產品的更多信息，請訪問以下網頁:
VitaGraft Kidney –
VitaGraft Liver –
GraftAssure –
DetermaIO –
DetermaCNI –
VitaGraft 腎臟 –
VitaGraft 肝臟 –
GraftAssure –
DetermaIO –
DetermaCNI –
VitaGraft, GraftAssure, DetermaIO, and DetermaCNI are trademarks of Oncocyte Corporation.
VitaGraft，GraftAssure，DetermaIO和DetermaCNI是Oncocyte公司的商標。
CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com
聯繫人：
傑夫·拉姆森
PCG 諮詢
（646）863-6893
jramson@pcgadvisory.com
譯文內容由第三人軟體翻譯。